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Chronic hepatitis C virus (HCV) infection is a systemic disease that leads to increased risks of
cirrhosis and its complications, as well as extrahepatic disturbances, including immune-related
disorders and metabolic alterations such as insulin resistance and steatosis. Recent accumulat-
ing evidence suggests that HCV infection can increase cardiovascular risk, and that viral erad-
ication can improve cardiovascular outcomes in the clinical setting. These data are strengthened
by evidence identifying potential mechanisms (in)directly linking HCV infection to vascular
damage. However, the high prevalence of both HCV infection and cardiovascular alterations,
as well as the presence of contrasting results not identifying any association between HCV infec-




Fibrosisinfection with cardiovascular risk. Further studies are needed to clarify definitively the role of
HCV infection in cardiovascular alterations, as well as the impact of viral eradication on
cardiovascular outcomes. These features are now more attractive, considering the availability
of new, safe, and very effective interferon-free antiviral agents for the treatment of HCV infec-
tion. This review aims to discuss carefully available data on the relationship between HCV infec-
tion and cardiovascular risk.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Infection by hepatitis C virus (HCV) accounts for a high pro-
portion of cases of chronic liver disease worldwide, and it has
spread pandemically [1]. As expected, longitudinal cohort
studies observed that patients with chronic hepatitis C
(CHC) have a high risk of liver-related morbidity and mortal-
ity, mostly due to the progression toward liver cirrhosis and its
complications [2,3]. Growing evidence, however, has moved
HCV infection from the traditional picture of a localized,
liver-focused disease, to the concept of a systemic disease cap-
able of producing extrahepatic manifestations [4]. In this com-
plex landscape, HCV-infected individuals have increased risks
of developing immune-related disorders, such as cryoglobu-
linemia and its sequelae, including B cell non-Hodgkin lym-
phoma, and systemic autoimmune diseases, all of which arise
from HCV lymphotropism [4].
Even stronger than the link between HCV infection and
immune-related disorders is the association, made first from
preliminary studies and then widely confirmed, between
HCV infection and metabolic alterations. Different lines of
evidence identified a higher prevalence of fatty liver infiltra-
tion, insulin resistance (IR), and diabetes in individuals
infected with HCV, with a ‘‘protective” serum lipid profile
characterized by lower low-density lipoprotein levels [5–12].
These metabolic changes arise from the ability of the virus to
affect liver lipid metabolism and insulin signaling, as con-
firmed by experimental studies and evidence that viral eradica-
tion corrects these metabolic alterations [5,12].
Besides these proven and well-recognized associations
between HCV infection and both immune-related and meta-
bolic disorders, recent emerging and growing evidence suggestsa link between HCV infection and neurological/psychiatric dis-
orders [13] and cardiovascular alterations [14]. However, both
HCV infection and cardiovascular alterations are common
conditions observed in a large proportion of the general pop-
ulation. It is difficult, therefore, to establish whether a simple
association exists between the two conditions, or whether other
pathogenic mechanisms directly or indirectly link chronic
HCV infection to cardiovascular disorders. Beyond being use-
ful from a speculative point of view, a better understanding of
this topic could have very relevant clinical consequences, due
to the availability of new, oral, safe, and highly effective antivi-
ral regimens for the treatment of HCV infection [15]. In this
review, we aimed to analyze the evidence linking HCV infec-
tion to a wide spectrum of cardiovascular alterations
(Fig. 1), the impact of HCV eradication on these vascular dis-
orders, and the potential mechanisms underlying these
associations.HCV infection and carotid atherosclerosis
Ishizaka and colleagues first reported an association between
carotid atherosclerosis and HCV infection in a cohort of
1992 Japanese subjects who had undergone general health-
screening tests, including ultrasonographic evaluation of the
carotid arteries [16]. Patients with HCV infection had a trend
toward a larger intima-media thickness (IMT) compared to
controls, as well as a significantly higher prevalence of carotid
plaques (64% vs. 25%). This association was maintained even
after adjusting for well-known metabolic confounders [16].
Targher and colleagues confirmed the association between
HCV infection and carotid atherosclerosis in a small Italian
study that compared patients with chronic liver diseases of
viral and nonviral causes to healthy controls [17]. The IMT
of patients with CHC was smaller compared to the IMT of
individuals with nonalcoholic fatty liver disease, but larger
compared to the IMT of controls. Moreover, CHC was an
independent risk factor for atherosclerosis. Consistent with
these data, other cross-sectional studies from both Western
and Asian populations reported a higher prevalence of carotid
atherosclerosis in individuals infected with HCV compared to
uninfected controls. This association was maintained after
adjustment for cardiometabolic confounders [18–21]. Simi-
larly, a high risk of carotid atherosclerosis was reported in
the setting of HCV-HIV co-infected patients [22–24].
Although the above studies found a strong and independent
link between HCV infection and carotid atherosclerosis, some
other reports in HCV mono-infected, HIV co-infected, and
hemodialysis patients found no association between HCV
infection and vascular alterations [25,26]. Due to the presence
of contrasting and inconclusive results, we recently performed
a meta-analysis of nine case-control studies to examine the
Fig. 1 Cardiovascular alterations and HCV infection. HCV infection is associated with a wide spectrum of cardiovascular alterations,
including cerebrovascular events, coronary/carotid atherosclerosis, high arterial stiffness, peripheral artery disease, myocardial injury,
cardiovascular events, and CCV-related death.
HCV and Heart 163effect of HCV infection on carotid plaques [27]. We found a
twofold higher risk of carotid plaques in individuals infected
with HCV compared to uninfected controls, without signifi-
cant heterogeneity among studies. Similar results were
obtained when we considered IMT as the outcome, instead
of carotid plaques. In addition, the impact of HCV infection
on the presence of carotid plaques was directly affected by
smoking status, with the effect of HCV infection being more
pronounced in populations with a high smoking prevalence.
HCV infection and coronary atherosclerosis
The first evidence of an association between HCV infection
and coronary atherosclerosis was from Vassalle and col-
leagues. These authors observed this link in a case-control
study of 491 patients with angiographic documentation of
coronary artery disease (CAD) (stenosis > 50%) and a control
group of 195 patients admitted to the same institute for rea-
sons other than CAD [28]. The authors found a higher preva-
lence of HCV infection in the CAD group compared to the
controls (6.3% vs. 2.0%), which remained higher after correc-
tion for cardiometabolic risk factors [28]. Similar results were
reported in a Turkish study of 139 HCV-seropositive and
225 HCV-seronegative patients, which found that HCV infec-
tion was an independent predictor of severity of coronary
atherosclerosis [29]. Consistent with these data, and in the dif-
ferent setting of hemodialysis patients, another Turkish study
of 26 HCV-infected and 26 HCV-uninfected patients suggestedthat HCV led to a significantly lower coronary flow reserve
compared to that of noninfected individuals, as assessed by
echocardiography [30]. Along this line, Butt and colleagues
observed a significantly higher risk of incidental CAD in sub-
jects with HCV infection compared to uninfected subjects in an
observational cohort of more than 150,000 US subjects [31].
Conversely, Forde and colleagues, in a large cohort of
adults (4809 with and 71,668 without HCV infection) followed
in general practices in the UK [32] found no difference in the
incidence of myocardial infarction (MI) according to HCV sta-
tus. Furthermore, a study in Pomerania evaluating the risks of
stroke and MI in HbsAg- or anti-HCV-positive patients com-
pared to noninfected subjects did not report an independent
effect of these infections [33].
HCV infection and cerebro-cardiovascular (CCV) events
Several case-control or cohort studies investigated the poten-
tial association between HCV infection and CCV events,
defined as ischemic stroke, MI, angina, congestive heart fail-
ure, or transient ischemic attack. These studies reported con-
trasting results, ranging from HCV infection as a risk factor
to HCV infection conferring a protective status [31,32,34–
41]. For example, considering cerebrovascular events, Liao
and colleagues performed a population-based cohort study
of 4094 Taiwanese adults newly diagnosed with HCV infection
and 16,376 Taiwanese controls matched by age and sex. HCV
infection was an independent predictor of stroke occurrence
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other hand, in a US case-control study of 126,926 HCV-
infected subjects and 126,926 controls, Butt and colleagues
showed a significantly lower prevalence of stroke in individuals
infected with HCV [41].
Due to the inconsistency of these results, we performed a
meta-analysis of aggregate data [27]. In the eight studies eval-
uated, we found that HCV infection had a significant negative
impact on CCV events. When we considered cerebrovascular
and cardiovascular events separately, we confirmed HCV as
a risk factor for both outcomes. As expected, however, we
found strong heterogeneity among the studies. Moreover, the
effect of HCV infection on CCV events was more pronounced
in populations at increased cardiovascular risk (i.e. with a high
prevalence of diabetes or hypertension).
HCV infection and other cardiovascular alterations
Some evidence links HCV infection to other cardiovascular
alterations. Maruyama and colleagues reported a direct associ-
ation between HCV infection and myocardial injury evaluated
by electrocardiography, echocardiography or thallium-201
myocardial scintigraphy in a relatively large cohort of 217
patients with CHC [42]. Consistent with these results, an Ital-
ian study reported that 52 patients infected with HCV had
higher left ventricular (LV) mass compared to 104 healthy,
normotensive subjects, but similar LV mass compared to 104
individuals with hypertension [43]. A recent Australian study
evaluated myocardial structure, function and tissue composi-
tion with cardiac magnetic resonance imaging in 21 patients
with CHC compared to uninfected controls. Patients with
CHC had significantly lower LV end-diastolic volume, reduced
stroke volume, lower postcontrast myocardial T1 time and
higher partition coefficient expression of myocardial fibrosis
[44]. Along this line, a Japanese cohort study of 7514 individ-
uals who underwent an annual checkup reported that HCV
infection was independently associated with a higher pulse
wave velocity [45]. Supporting the wide association between
HCV infection and cardiovascular alterations, a Taiwanese
cohort study of 7641 individuals infected with HCV and
30,564 matched controls reported a higher risk of developing
peripheral artery disease in patients infected with HCV com-
pared to uninfected controls. This risk was greater in older
patients and independent of conventional risk factors [46].
HCV infection and cardiovascular mortality
Although all of the above studies suggested an increased car-
diovascular risk in patients with HCV infection, these studies
used surrogate endpoints for cardiovascular outcomes. The
strongest outcome is represented by cardiovascular mortality.
Some studies have evaluated the impact of HCV infection on
cardiovascular mortality, reporting contrasting data. In 2008,
Guiltinan and colleagues studied a US cohort of 10,259
HCV-infected and 10,259 uninfected matched blood donors.
They were the first to report that HCV infection may increase
cardiovascular mortality [47]. Similar data were later observed
in a Taiwanese cohort of 18,541 anti-HCV seronegative and
1095 anti-HCV seropositive individuals [48]. However, a recent
population-based cohort study of an Australian sample of
29,571 individuals receiving opioid substitution therapyreported no association between HCV infection and cardiovas-
cular mortality [49]. Due to the uncertainty among these stud-
ies, we performed a meta-analytic evaluation of the available
data. We found clear evidence that HCV infection increases
the risk of cardiovascular disease-related mortality [27].HCV infection and cardiovascular injury: potential mechanisms
of virus-related damage
Evidence supporting the association between HCV infection
and cardiovascular alterations prompts us to identify potential
mechanism(s) linking these two highly prevalent conditions
[50,51]. Other than the diverse factors and metabolic comor-
bidities that are more prevalent in HCV-infected compared
to noninfected individuals, the proinflammatory and profibro-
genic HCV-related environment and a direct viral effect could
be advocated as causes of cardiovascular alterations (Fig. 2).
HCV infection has been associated with increased visceral
fat [25]. Additionally, a relationship was found between
HCV viral load and the visceral adiposity index [52], a marker
of total body fat content and metabolic dysfunction. HCV is
able to modulate lipid metabolism and insulin signaling, lead-
ing to a higher prevalence of diabetes and fatty liver infiltration
in this clinical setting [5]. Consistent with this observation,
recent experimental studies showed that HCV induces an
increase in hepatic levels of not only triglycerides but also
cholesterol esters and sphingolipids, which are potentially
involved in mechanisms leading to HCV-induced steatosis
and lipotoxicity [53,54]. Among subjects infected with HCV,
the presence of steatosis was found to be an independent risk
factor for carotid atherosclerosis [18]. Despite the reported
high prevalence of these metabolic alterations in CHC, differ-
ent studies have shown that HCV-infected patients are charac-
terized by a favorable lipoprotein profile: low LDL and VLDL
cholesterol. Taken together, these observations lead us to
hypothesize that although HCV-infected individuals have a
similar prevalence of metabolic syndrome compared to unin-
fected subjects, they may have an increased cardiovascular risk
due to induction of well-recognized cardiovascular risk factors
(i.e. obesity, IR, type 2 diabetes, and steatosis).
HCV infection could lead to increased cardiovascular risk
by inducing a systemic inflammatory status and oxidative
stress. There is evidence that patients infected with HCV are
characterized by chronic inflammation induced by innate, nat-
ural killer cell (NK)-mediated, and adaptive, T-helper-1-
mediated responses [55]. This immune response can lead to
lower adiponectin and higher serum tumor necrosis factor
(TNF) alpha and interleukin (IL)-6 levels [56,57], with adipo-
nectin being inversely, and TNF alpha and IL-6 being directly,
related to cardiovascular alterations. Hepatic steatosis and vis-
ceral obesity could contribute to this inflammatory status by
prompting production of reactive oxygen species and inflam-
matory cytokines [18]. Along this line, endothelial damage
directly related to the HCV infection [58,59], or expression
of a vasculitis due to mixed cryoglobulinemia [60] could fur-
ther contribute to the link between HCV infection and higher
cardiovascular risk.
The impact of HCV-related inflammation on cardiovascu-
lar risk could be higher in patients with more liver damage,
although most studies assessing the impact of HCV infection
on cardiovascular alterations have not been accounted for this
Fig. 2 Mechanisms potentially linking HCV infection with increased cardiovascular risk. HCV can directly and indirectly interfere with
glucose and lipid metabolism, leading to IR, diabetes, fatty liver, and visceral obesity. These metabolic factors, together with lifestyle, may
increase the cardiovascular risk of HCV-infected patients. In addition, HCV itself may lead to cardiovascular alterations via direct and
indirect mechanism(s). On the one hand, proinflammatory and profibrogenic environments leading fibrogenesis in the liver could be
systemically activated, enhancing the development of cardiovascular alterations. On the other hand, the presence of direct viral
mechanisms could be hypothesized.
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liver damage reported a link between it and cardiovascular
injury. Among patients with biopsy-proven CHC, we found
that the presence of severe liver fibrosis was an independent
risk factor for carotid atherosclerosis [19]. Consistent with
these data, two recent studies found a link between myocardial
injury and both the severity of liver damage and necroinflam-
matory activity among patients infected with HCV [42,44].
Similarly, a recent cohort study reported that HCV-infected
patients with higher liver stiffness values had a greater risk
of developing cardiovascular events compared to those with
lower stiffness values [61]. These data suggest that the proin-
flammatory and profibrogenic environment leading to fibroge-
nesis in the liver of patients infected with HCV may also be
systemically activated, further enhancing the development of
cardiovascular lesions.
Finally, there are some evidences of a direct link between
HCV viral load and cardiovascular alterations. An Italian
study [18] showed that patients with CHC and carotid
atherosclerosis had higher serum HCV-RNA levels than those
without carotid atherosclerosis. Similarly, a Japanese study
reported a direct link between HCV-RNA viral load and
myocardial injury [42]. Consistent with these data, Boddi
and colleagues found positive-strand HCV-RNA in carotid
plaques from anti-HCV-positive patients but not in plaques
of anti-HCV-negative patients [62]. While requiring careful
interpretation, these data suggest a direct role of HCV infec-
tion in vascular damage.Does antiviral therapy affect cardiovascular risk among HCV-
infected individuals?
As HCV infection may increase cardiovascular risk, a clinically
relevant issue is whether treating the infection can improve car-
diovascular outcomes. A Japanese study of 200 individuals
infected with HCV reported an improvement in myocardial
injury in patients who achieved a sustained viral eradication
after PEG-IFN plus ribavirin therapy, a transitory improve-
ment in those who relapsed, and no improvement in nonre-
sponders [42]. A significantly higher risk of carotid
atherosclerosis was found in HCV-infected, but not in HCV-
cleared patients, compared to uninfected subjects [25]. A
Taiwanese community-based study of 18,541 anti-HCV
seronegative and 1095 anti-HCV seropositive subjects reported
an increase in mortality from circulatory diseases compared to
uninfected subjects in patients with anti-HCV and detectable
HCV-RNA, but not in those with undetectable HCV-RNA
[48]. These two last studies provide indirect evidence of a
potential positive impact of viral eradication on cardiovascular
outcomes.
Another Taiwanese study of 23,665 residents reported that
the risk of lethal cerebrovascular events progressively
increased from patients who were anti-HCV-positive with
undetectable HCV RNA, to patients with a low viral load,
and further to those who were highly viremic, compared to
anti-HCV-negative patients [63]. Two other Taiwanese cohort
166 S. Pettastudies in individuals infected with HCV found a significant
reduction in the occurrence of acute coronary syndrome,
stroke, and end-stage renal disease among those who under-
went PEG-IFN-based antiviral therapy compared to those
who did not receive these treatments. These findings were fur-
ther confirmed in a subgroup of diabetic patients [36,39]. A
preliminary study of a small group of 21 Italian HCV-
infected patients with diabetes found improved fasting baseline
blood glucose levels after direct antiviral agent (DAA)-based
HCV eradication [64]; however, the effect of DAAs on diabetes
outcomes is worthy of further investigation [65].
All of the above quoted data need to be carefully inter-
preted due to the different designs of the studies and the lack
of data regarding outcomes of antiviral therapy. Future
prospective studies should be performed to give conclusive
answers to this relevant clinical area of research.Conclusions
Growing evidence from multiple clinical and experimental
studies, as well as meta-analysis results suggests that HCV
infection increases cardiovascular risk in terms of atherosclero-
sis, myocardial injury, CCV events, and cardiovascular mortal-
ity, especially in patients at increased cardiovascular risk.
Preliminary and indirect data provide evidence of a potential
effect of HCV eradication on cardiovascular outcomes. Meta-
bolic alterations related to HCV infection, the proinflamma-
tory and profibrogenic status associated with HCV infection,
and liver damage, as well as potential direct viral mechanisms
could explain the reported link between HCV infection and
increased cardiovascular risk. However, heterogeneity among
studies in terms of design, baseline characteristics of the popu-
lations, methods used for the definition of cardiovascular out-
comes and HCV infection, as well as lack of data on outcomes
of antiviral therapy and on the severity of liver damage
strongly limit the available evidence. Thus, further prospective
data are needed to define the impact of HCV on cardiovascular
outcomes and of HCV eradication on improvement of these
outcomes. This issue is of particular interest in the era of safe
and effective interferon-free regimens for HCV treatment. If
definitively confirmed, these data could lead to the treatment
of HCV infection not only to reduce risks of liver disease pro-
gression/complications, but also to reduce risks of extrahepatic
(including cardiovascular) complications.Conflict of Interest
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